Opdivo and Faeces discolored - a phase IV clinical study of FDA data

Summary:

Faeces discolored is found among people who take Opdivo, especially for people who are male, 60+ old, have been taking the drug for 1 - 6 months.

The phase IV clinical study analyzes which people take Opdivo and have Faeces discolored. It is created by eHealthMe based on reports of 41,614 people who have side effects when taking Opdivo from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Jan, 27, 2023

41,614 people reported to have side effects when taking Opdivo.
Among them, 32 people (0.08%) have Faeces discolored.

What is Opdivo?

Opdivo has active ingredients of nivolumab. eHealthMe is studying from 41,650 Opdivo users for its effectiveness, alternative drugs and more.

What is Faeces discolored?

Faeces discolored is found to be associated with 2,524 drugs and 1,544 conditions by eHealthMe.

Number of Opdivo and Faeces discolored reports submitted per year:

Time on Opdivo when people have Faeces discolored *:

Gender of people who have Faeces discolored when taking Opdivo *:

female: 16.13 %
male: 83.87 %

Age of people who have Faeces discolored when taking Opdivo *:

Common drugs people take besides Opdivo *:

Common side effects people have besides Faeces discolored *:

Rashes (redness): 7 people, 21.88%
Gastrointestinal Haemorrhage (bleeding gastrointestinal tract): 6 people, 18.75%
Urticaria (rash of round, red welts on the skin that itch intensely): 6 people, 18.75%
Disseminated Intravascular Coagulation (systemic activation of blood coagulation): 6 people, 18.75%
Malignant Neoplasm Progression (cancer tumour came back): 6 people, 18.75%
Diarrhea: 6 people, 18.75%
Anaemia (lack of blood): 6 people, 18.75%
Myositis (inflammation of the muscles): 5 people, 15.62%
Gastroduodenal Ulcer: 5 people, 15.62%
Erythema Multiforme (a type of hypersensitivity reaction): 5 people, 15.62%

Common conditions people have *:

Metastatic Renal Cell Carcinoma (spreadable kidney cell tumour): 9 people, 28.12%
Gastric Cancer (stomach cancer): 6 people, 18.75%
Ulcerative Colitis (inflammatory bowel disease (ibd). it causes swelling, ulcerations, and loss of function of the large intestine): 5 people, 15.62%
Malignant Melanoma (skin cancer rises from melancytes): 5 people, 15.62%
Disseminated Intravascular Coagulation (systemic activation of blood coagulation): 5 people, 15.62%
Thrombophlebitis (swelling (inflammation) of a vein caused by a blood clot): 2 people, 6.25%
Non-Small Cell Lung Cancer Recurrent (type of epithelial lung cancer reoccurrence): 2 people, 6.25%
Lung Neoplasm Malignant (cancer tumour of lung): 2 people, 6.25%
Cerebral Infarction (less blood supply to brain resulting tissue damage): 2 people, 6.25%
Stress And Anxiety: 1 person, 3.12%

* Approximation only. Some reports may have incomplete information.

Do you take Opdivo and have Faeces discolored?

Check whether Faeces discolored is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

How severe was Faeces discolored and when was it recovered:

Faeces discolored in Opdivo

Expand to all the drugs that have ingredients of nivolumab:

Faeces discolored and drugs with ingredients of nivolumab

Alternative drugs to, pros and cons of Opdivo:

Opdivo (41,650 reports)

Common Opdivo side effects:

Death: 8,175 reports
Rashes (redness): 1,836 reports
Diarrhea: 1,818 reports
Fever: 1,748 reports
Pneumonia: 1,425 reports
Fatigue (feeling of tiredness): 1,273 reports

Browse all side effects of Opdivo:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Faeces discolored treatments and more:

Faeces discolored (24,035 reports)

COVID vaccines that are related to Faeces discolored:

Common drugs associated with Faeces discolored:

All the drugs that are associated with Faeces discolored:

Faeces discolored (2,524 drugs)

Common conditions associated with Faeces discolored:

High blood pressure: 1,160 reports
Atrial fibrillation/flutter: 1,103 reports
Pain: 852 reports

All the conditions that are associated with Faeces discolored:

Faeces discolored (1,544 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on nivolumab (the active ingredients of Opdivo) and Opdivo (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.